This was a retrospective cohort study which included all histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 at a tertiary care centre. This study was performed in line with STROCSS criteria. The following clinicopathological data was retrieved from the histopathological records- age, tumor size, nodal involvement, lymphovascular/ perineural invasion, and Bloom Richardson grading. Routine histopathological processing was done followed by immunohistochemical analysis for ER, PR, HER2, Ki67 and AR. All the cases were categorised into Luminal A, B, Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification. Further, all the cases were categorised into HER2 negative (no staining or incomplete weak membrane staining in ≤10% tumor cells), HER2 3+ (complete membranous staining) and HER2 low (1-2+ staining without amplification on ISH) based on consensus of two pathology consultants. The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers.
Study Type
OBSERVATIONAL
Enrollment
70
Immunohistochemistry for HER2
VMMC SJH
New Delhi, India
Age (in years)
It will be measured for HER2 low breast cancer patients
Time frame: JANUARY 2022- DECEMBER 2023
Tumor stage (categorised from T1-T4)
This denotes status of stage of tumor- T1, T2, T3, T4. It will be measured for HER2 low breast cancer patients
Time frame: JANUARY 2022- DECEMBER 2023
N stage (categorised from N0-N3)
This denotes status of nodal involevement- N0, N1, N2 or N3. It will be measured for HER2 low breast cancer patients
Time frame: JANUARY 2022- DECEMBER 2023
Tumor grade (categorised from G1-G3)
This denotes whether tumor is well, modeartely or porrly differentiated. It will be measured for HER2 low breast cancer patients.
Time frame: JANUARY 2022- DECEMBER 2023
Surrogate molecular classification (Categorised as luminal/ triple negative)
This denoted the molecular classification of breast cancer based on ER, PR, Her2 expression.
Time frame: JANUARY 2022- DECEMBER 2023
Androgen receptor expression (Denoted as present or absent)
This denoted the immunohistochemical expression of androgen receptor which would be evaluted in all cases of HER2 low breast cancer
Time frame: JANUARY 2022- DECEMBER 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.